David A. Siegel Kiniksa Pharmaceuticals, Ltd. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$11.39 - $16.23 $823,497 - $1.17 Million	-72,300 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$13.22 - $19.09 $575,070 - $830,415	-43,500 Reduced 37.56%	72,300 $1.01 Million
Q1 2021 May 17, 2021	SELL	$16.68 - $23.97 $955,764 - $1.37 Million	-57,300 Reduced 33.1%	115,800 $2.14 Million
Q4 2020 Feb 16, 2021	SELL	$14.8 - $21.15 $386,280 - $552,015	-26,100 Reduced 13.1%	173,100 $3.06 Million
Q3 2020 Nov 16, 2020	BUY	$15.21 - $25.53 $2.9 Million - $4.86 Million	190,400 Added 2163.64%	199,200 $3.05 Million
Q2 2020 Aug 14, 2020	BUY	$15.08 - $26.0 $132,704 - $228,800	8,800 New	8,800 $224,000

1.85M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $1.4B
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.